Announcements Trials
Browse Landscape

Clinical Trials

2 trials
RecentStart dateEnrollment
RC-18 × Clear all

Phase

Phase 3 1Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Lymphoma, Follicular 2Arthritis, Rheumatoid 2

Interventions

Cisplatin 3180Cyclophosphamide 3173Carboplatin 2960Radiotherapy 2772Paclitaxel 2708Gemcitabine 2552pembrolizumab 2370Bevacizumab 2195Docetaxel 2191Fluorouracil 1839Capecitabine 1815Oxaliplatin 1724Dexamethasone 1593Nivolumab 1577Doxorubicin 1501Rituximab 1480Magnetic Resonance Spectroscopy 1368Etoposide 1344Irinotecan 1241Leucovorin 1217Drug Therapy 1190Cytarabine 1127Pemetrexed 1068fludarabine 1035Specimen Handling 987Vincristine 964Prednisone 940Cetuximab 939Trastuzumab 937Lenalidomide 932

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements
NCT03016013 2024-09-26

A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects with Inadequate Response to MTX Due to Treat Moderate and Severe Rheumatoid Arthritis.

RemeGen Co., Ltd.

Phase 3 Completed
479 enrolled
Lymphoid

Arthritis, Rheumatoid, Lymphoma, Follicular

NCT02882087 2019-04-03

A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Inadequate Response to TNF-α Antagonists Due to Treat Moderate and Severe Rheumatoid Arthritis

RemeGen Co., Ltd.

Phase 2 Terminated
60 enrolled
Lymphoid

Arthritis, Rheumatoid, Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡